We recently characterized a CD4 ⍣ T cell population expressing the IL-2Rα chain (CD25), producing IL-10 and resisting clonal deletion induced by viral superantigen (vSAG) encoded by mouse mammary tumor virus [MMTV(SW)]. We now report that these apoptosis-resistant cells are generated in the thymus but not from the immature CD4 ⍣ CD8 ⍣ thymocytes. They migrate from the thymus and are found in the periphery from at least the 10th day of life, after which they expand with the same kinetics in normal and MMTV(SW)-infected mice. Their strong capacity for expansion in the periphery makes this population insensitive to thymectomy in adulthood. CD4 ⍣ CD25 ⍣ cells were totally dependent on exogenous IL-2 for growth in vitro and in vivo, and were missing in IL-2 knockout (KO) mice. The absence of this population and/or an inability to produce IL-10 may be the missing link between IL-2Rα KO, IL-2 KO and IL-10 KO mice, which all die of inflammatory bowel disease.
Introduction
Induction of tolerance involves a complex machinery which leads to the death or functional silencing of the target cells. Tolerance of viral superantigen (vSAG) encoded by endogenous mouse mammary tumor viruses (MMTV) is mainly due to clonal deletion of vSAG-specific T cells (1) (2) (3) (4) . Elimination of these reactive T cells occurs rapidly and early after birth. Injection of vSAG-expressing cells into MMTV-negative mice may induce both anergy and clonal deletion (5, 6) . Infectious MMTV transmitted via milk to newborn mice induces clonal anergy and gradual clonal deletion (7) (8) (9) (10) . However, potentially reactive T cells persist, even several months after birth (8, 9) . We recently analyzed this residual population following neonatal MMTV(SW) infection (10) . We identified a CD4 ϩ T cell subpopulation which expresses the IL-2Rα chain (CD25) and is resistant to vSAG-induced clonal deletion. Expression of CD25 thus defines two cell subpopulations with different behavior. Clonal deletion induced by vSAG occurs exclusively at the expense of the CD4 ϩ CD25 -population, while the number of cells in the CD25 ϩ subset remains constant. The cytokine profile is also different between the two populations, as CD25 -cells produce IL-2 and not IL-10, while CD25 ϩ cells France). IL-2 knockout (KO) mice, derived by Schorle et al. (15) , were a gift from J. DiSanto and P. Froissard (Hô pital Necker and Institut Pasteur, Paris, France). IL-2Rα KO mice (11) and IL-10 KO mice (16) were purchased from the Jackson Laboratory (Bar Harbor, ME).
Antibodies and immunofluorescence studies
The following antibodies were used: anti-CD4 (clone GK1.5) (17) , anti-CD8 (clone 53-6.7) (18), anti-V β 6 (clone 44.22.1) (19) , anti-V β 8.2 (clone F23.2) (20) , anti-CD25 (clone PC61) (21) , anti-CD3 (clone 145.2C11) (22) and anti-BrdU (clone 76/7) (23) (gift from T. Ternynck, Institut Pasteur, Paris, France).
For double labeling, cells were incubated with biotinylated antibodies followed by simultaneous incubation with streptavidin-phycoerythrin (PE-SAV; Caltag, San Francisco, CA). Fluoresceinated antibody SAV-TriColor (Caltag) was used for triple labeling and SAV-allophycocyanin (APC-SAV) (Molecular Probe Europe, Leiden, The Netherlands) for quadruple labeling. Fluoresceinated and biotinylated antibodies were prepared in our laboratory. PE-coupled antibodies were purchased from Caltag. Double and triple labeling experiments were performed on CD4 ϩ T cells purified by B cell and CD8 ϩ T cell depletion, as described below.
Flow cytometry was performed using a FACScan or a FACS Vantage cytometer (Becton-Dickinson, Mountain View, CA) with the Lysys II program for data acquisition and analysis. Dead cells were excluded on the basis of forward and side light scatter. Between 1 and 5ϫ10 4 cells were acquired in each experiment.
Cycling and post-cycling cell analysis DNA-synthesizing cells were labeled in vivo with BrdU. Pulse labeling (two injections at a 4 h interval) was used to detect cycling cells and to study their progeny. Continuous labeling was performed with two i.p. injections of BrdU daily (1 mg each, 7 h apart) for 3 days. This protocol labeled all cells undergoing DNA synthesis and all their progeny. Lymph node and thymic cells were stained with anti-CD4-or anti-CD8-Red613 (Sigma), anti-CD8 or anti-CD25-PE and biotinylated anti-V β 6 or anti-V β 8.2 plus APC-SAV. For BrdU detection, triplestained cells were fixed in 200 µl of 1% paraformaldehyde containing 0.01% Tween 20 (Sigma) for 48 h at 4°C. Cells were washed in PBS and then in 40 mM Tris-HCl, pH 8.0, containing 10 mM NaCl and 6 mM MgCl 2 , and were incubated for 1 h at 37°C in the same buffer containing 50 Kunitz units of bovine pancreatic deoxyribonuclease I (Pharmacia, Uppsala, Sweden). After washing in PBS, lymphocytes were incubated in PBS containing 0.5% Tween 20, anti-BrdU mAb, and then with FITC-conjugated anti-mouse IgG1 (Southern Biotechnologies, Birmingham, AL), each for 30 min at room temperature. This technique has been described in detail elsewhere (24) . Immunolabeled cells were analyzed in a duallaser FACS Vantage cytometer using Lysys II software. The percentages of BrdU ϩ cells in the CD25 ϩ and CD25 -subsets were determined after acquisition of gated CD4 ϩ V β 6 ϩ or CD4 ϩ V β 8.2 ϩ cells.
Cell preparation and culture
Cells were prepared from pooled inguinal and axillary lymph nodes. Lymph node cells were first enriched in CD4 ϩ T cells by depletion of CD8 ϩ T cells then B cells. Briefly, lymph node cells were incubated with purified anti-CD8 antibody and then with goat anti-rat Ig antibody-coated magnetic beads (Dynabeads; Dynal, Oslo, Norway). CD8 ϩ T cells were removed with a magnet. B cells were depleted using goat anti-mouse Ig-coated beads. Purified CD4 ϩ T cells were labeled with anti-CD4-PE, and anti-CD25-FITC, CD4 ϩ CD25 ϩ and CD4 ϩ CD25 -T cells were then sorted using a FACS Vantage apparatus (Becton Dickinson). Cells were 97-99% pure.
For anti-TCR cross-linking, 96-well round-bottomed culture plates (Nunc, Roskilde, Denmark) were coated for 2 h with purified anti-CD3 antibody (10 µg/ml) and washed with RPMI 1640 medium (Gibco, Grand Island, NY) supplemented with 5% FCS. CD4 ϩ T cells (10 4 ) were plated in 100 µl of culture medium per well (RPMI 1640 supplemented with 100 IU/ml penicillin, 100 µg/ml streptomycin, 1% sodium pyruvate, 10 -5 M β-mercaptoethanol and 10% FCS). Recombinant IL-2 (Becton Dickinson Labware, Bedford, MA) was added to some of the wells at a final dilution of 500 U/ml. Cultures were set up in triplicate and incubated for 4 days; proliferation was assessed by incorporation of 
Study of thymic migrants and thymectomy
Mice between 7 and 8 weeks old were injected intrathymically with 10 µl of 5 mg/ml FITC solution and killed 15-16 h later. Peripheral lymph nodes were removed. Lymph node cells were prepared and washed twice in RPMI 1640/50% FCS, then once with RMPI 1640/5% FCS. Cells were depleted of B cells and CD8 T cells, then labeled with anti-CD25-PE and biotinylated anti-V β 6 or anti-V β 8.2, and revealed by SAVTriColor. CD25 expression was analyzed within the total CD4 ϩ lymph node population or within the gated FITC-positive recent thymic emigrants.
Thymectomy was performed at 4 weeks of age on anesthetized mice by suction.
Transfer of CD4 ϩ lymph node T cells into nude mice CD4 ϩ T cells from peripheral BALB/c and BALB/c(SW) lymph nodes were purified using magnetic beads. Total CD4 ϩ cells were injected i.v. into BALB/c nu/nu mice (3ϫ10 5 per mouse). The expansion capacity of CD4 ϩ CD25 -and CD4 ϩ CD25 ϩ cells was analyzed 4 weeks later in the peripheral lymph nodes by measuring the absolute number of CD4 ϩ CD25 -and CD4 ϩ CD25 ϩ cells.
Oligonucleotides
All primers were obtained from Bioprobe (Montreuil, France). The following specific primer sequences were used: IL-10 5Ј primer, AGA GCA AGG CAG TGG AGC AG; IL-10 3Ј primer, GGG ATG ACA GTA GGG GAA CC; HPRT 5Ј primer, GTA ATG ATC AGT CAA CGG GGG AC; HPRT 3Ј primer, CCA GCA AGC TTG CAA CCT TAA CCA.
PCR analysis of cDNA (RT-PCR)
Expression of mRNA for IL-10 and HPRT was tested on purified CD4 ϩ lymph node T cells after 6 h of culture in the presence of coated anti-CD3 mAb.
Crude RNA was extracted from 10 6 cells using TRIzol Reagent (Life Technologies, Cergy-Pontoise, France), according to the manufacturer's instructions, with the addition of 10 µg of yeast transfer RNA as carrier. RNA was reversed transcribed into cDNA with random oligonucleotides. PCR reactions were performed in 50 µl volumes containing 2 µl of cDNA sample, 50 U/ml Taq polymerase (Life Technologies), 0.25 µM 5Ј and 3Ј primers, 50 µM each dNTP, 1.5 mM MgCl 2 , and 1ϫPCR buffer. cDNAs were subjected to 35 cycles at 94°C for 1 min, 60°C for 1 min and 72°C for 1 min, followed by a 10 min extension step at 72°C. The amplified products were analyzed on 1.5% agarose gel. Fragments of DNA were photographed and are presented in negative form.
Results

CD25 ϩ T cells resistant to vSAG-induced clonal deletion accumulate in the thymus of MMTV(SW)-infected mice
We have recently shown that clonal deletion induced by MMTV(SW)-encoded vSAG occurs at the expense of a CD4 ϩ V β 6 ϩ CD25 -population, sparing a CD4 ϩ V β 6 ϩ CD25 ϩ subset (10). Here we studied the behavior of this population during ontogeny in the thymus and in the periphery. Development of the CD4 ϩ CD25 ϩ subset was compared in normal BALB/c and infected BALB/c(SW) mice. As shown in Fig.  1(A) , the total number of CD4 ϩ V β 6 ϩ T cells increased in the lymph nodes of BALB/c mice up to 7 weeks of age, and clonal deletion in BALB/c(SW) mice started between 4 and 7 weeks of age. The CD4 ϩ V β 6 ϩ CD25 ϩ pool increased from 10 days onward, to plateau at 7-8 weeks of age. Ontogenesis of the CD25 ϩ pool was identical in BALB/c and BALB/c(SW) mice (Fig. 1B) .
Clonal deletion of CD4 ϩ V β 6 ϩ T cells in infected mice was less extensive in the thymus than in the lymph nodes. It took place between 4 and 7 weeks of age, when normal thymic involution is beginning ( Fig. 2A) [8.7 Ϯ 1.8ϫ10 5 CD4 ϩ V β 6 ϩ cells in BALB/c(SW) compared to 12.7 Ϯ 2.3ϫ10 5 in controls (P Ͻ 0.02) at 7-8 weeks of age, and 3.6 Ϯ 0.4ϫ10 5 CD4 ϩ V β 6 ϩ compared to 7.4 Ϯ 0.7ϫ10 5 (P Ͻ 0.001) at 9-16 weeks of age]. The CD4 ϩ V β 6 ϩ CD25 ϩ subset increased before 4 weeks of age in the thymus of MMTV(SW)-infected mice, reaching twice the number found in normal mice between 4 and 7 weeks of age (Fig. 2B) . The phenotype and generation of CD4 ϩ single-positive (SP) thymocytes expressing CD25 was then examined in the thymus of normal and infected mice.
CD4 ϩ SP thymocytes expressing CD25 are similar to fully mature T cells and do not derive directly from CD4 ϩ CD8 ϩ double-positive (DP) cells CD4 ϩ CD8 -thymocytes with a high TCR density are a mixture of fully mature (CD24 -, Qa-2 hi ) and semi-mature (CD24 ϩ , Qa-2 lo ) cells. As shown previously (24) , DP thymocytes first give rise to semi-mature cells and the fully mature phenotype is reached at least 1 week later. The maturity of CD4 SP thymocytes expressing CD25 was estimated by measuring CD24 (HSA) and Qa-2 expression, and was compared to lymph node T cells and DP thymocytes ( Table 1 ). The great majority (90%) of CD25 ϩ CD4 ϩ SP thymocytes were CD24 -, like peripheral T cells, but 43.5% only were Qa-2 hi . CD25 ϩ DP thymocytes had a more complex phenotype, as 60% were CD24 -and only 14% were Qa-2 hi .
The proliferative activity of mature CD4 ϩ SP and immature DP expressing CD25 was estimated by measuring BrdU incorporation 1 h after a double pulse. The proportions of labeled cells were 2.1 Ϯ 0.3% of CD4 ϩ CD8 -CD25 ϩ and 6.6 Ϯ 1.7% of CD4 ϩ CD8 ϩ CD25 ϩ thymocytes. After repeated BrdU injections for 3 days, these percentages increased to 13 Ϯ 2 of CD4 ϩ SP and 88 Ϯ 3 of DP cells. These results showed that the proliferative activity of CD25 ϩ thymocyte subpopulations was of the same order as that of the corresponding total CD4 ϩ SP and DP cells (25) , and that CD25 ϩ SP cell generation was not due to preferential expansion. Similar results were Thymocytes and lymph node cells from BALB/c mice were fourcolor-labeled with anti-CD4, anti-CD8, anti-CD25 and anti-CD24 (HSA) or anti-Qa-2. The expression of CD24 or Qa-2 by gated CD25 ϩ cells was assessed in a FACS Vantage cytometer.
found in V β 6 ϩ CD25 ϩ SP thymocytes from BALB/c and BALB/c(SW) mice.
The kinetics of CD25 ϩ CD4 ϩ SP and DP thymocyte genera- tion were compared using the BrdU pulse method (24) , and were found to be similar for CD25 ϩ DP cells and total DP cells. A transient increase in the number of BrdU ϩ CD25 ϩ CD4 ϩ SP cells was observed on day 3 (Fig. 3) , but it was too weak to be considered as significant. The kinetics of generation of CD25 ϩ and CD25 -CD4 SP cells strongly expressing V β 6 or V β 8.2 TCR chains were compared in BALB/c and BALB/c(SW) mice at 7-8 weeks of age. The results, expressed as percentages of BrdU ϩ cells, are represented in Fig. 4 . No clear generation of CD25 ϩ CD4 ϩ SP cells was observed: the percentages of BrdU ϩ cells in all groups remained low and roughly constant throughout the period studied, even in SP cells of BALB/c(SW) mice. In the same conditions, generation of CD4 ϩ CD25 -cells expressing V β 6 or V β 8.2 was clearly observed on days 3-4.
In conclusion, phenotype and kinetic data gave no evidence that CD4 ϩ CD25 ϩ SP cells were generated directly from CD25 ϩ DP cells. Accumulation of CD25 ϩ CD4 ϩ SP cells in the thymus of infected mice was not linked to higher proliferation rate. CD25 ϩ cells migrate from the thymus to the periphery: their high expansion capacity maintains a constant peripheral level after thymectomy
The capacity of CD25 ϩ CD4 ϩ T cells to migrate from the thymus to the periphery was studied after intrathymic injection of FITC. The percentage of CD25 ϩ cells within migrants and resident T cells was identical ( Table 2 ), suggesting that CD25 ϩ cells in the periphery can originate in the thymus. However, thymectomy between 4 and 5 weeks of age did not modify the number of CD25 ϩ CD4 ϩ T cells in the periphery (Fig. 5) , even when tested 19 months later. To see if CD25 ϩ cells could expand in the periphery, purified CD4 ϩ T cells were injected i.v. into athymic nude mice. As shown in Table 3 , both the CD25 -and CD25 ϩ CD4 ϩ T cell compartments were reconstituted, with even a more rapid reconstitution of the CD25 ϩ compartment. [We have already shown that CD25 -cells cannot generate CD25 ϩ cells when transferred in vivo (10) ].
The CD4 ϩ V β 6 ϩ CD25 ϩ subset of MMTV(SW)-infected mice is resistant to clonal deletion and is hypo-responsive to vSAG in vivo (10) . We transferred CD4 ϩ T cells from MMTV(SW)-infected mice to see if the capacity of vSAG-specific T cells to expand in vivo was impaired. Interestingly, this specific partial anergy of CD4 ϩ CD25 ϩ cells did not modify their capacity to expand in vivo (Table 3) . CD4 ϩ CD25 ϩ cells need IL-2 for growth in vitro and in vivo
We have already shown that CD4 ϩ CD25 ϩ cells in the periphery do not express IL-2 mRNA, even after anti-CD3 cross-linking in vitro. Anti-CD3 does not induce their proliferation in vitro either (10) . IL-2 was thus apparently needed for CD4 ϩ CD25 ϩ T cell expansion in vitro. Sorted CD4 ϩ CD25 ϩ and CD4 ϩ CD25 -lymph node T cells were stimulated in vitro with anti-CD3 plus or minus IL-2. As shown in Table 4 , exogenous IL-2 was not Purified CD4 ϩ T cells were injected i.v. into BALB/c nu/nu mice (3ϫ10 5 per mice). Four weeks after transfer, peripheral lymph nodes were removed and cells were tested for the expression of CD4, CD25 and V β 6. Results were expressed in absolute number of cells Ϯ SD per lymph node (at least three mice were tested per group).
needed for CD4 ϩ CD25 -cell growth, while exogenous IL-2 was required for CD4 ϩ CD25 ϩ T cell growth. Exogenous IL-2 did not increase CD25 -cell proliferation, while CD25 ϩ cells proliferated 3 times more than CD25 -cells.
CD4 ϩ CD25 ϩ also need IL-2 for expansion in vivo. As shown in Fig. 5 , CD4 ϩ CD25 ϩ T cells were absent from the periphery and from CD4 ϩ SP thymocytes of IL-2 KO mice. Interestingly, these mice still had a high percentage of CD25 ϩ cells within the CD4 -CD8 -CD3 -precursor thymocyte compartment, in which differentiation is known to be dependent on two receptor/ligand pairs, i.e. c-kit-SCF and IL-7R-IL-7 (26).
CD4 T cells from IL-2 KO and IL-2Rα KO mice do not include IL-10 mRNA-expressing cells
We have already shown that CD25 ϩ CD4 ϩ T cells express IL-10 mRNA and that CD25 -CD4 ϩ T cells do not, even after anti-CD3 stimulation in vitro (10) . As the CD25 ϩ population was missing in IL-2 KO mice and, of course, in IL-2Rα KO mice, we expected that IL-10 mRNA-expressing cells should be missing in their CD4 ϩ T cells. IL-10 mRNA expression was analyzed in purified CD4 ϩ lymph node T cells of normal mice, IL-2Rα KO mice and IL-2 KO mice after 6 h of incubation with anti-CD3. CD4 T cells of IL-10 KO mice served as negative controls. As shown on Fig. 6 , CD4 ϩ T cells from normal mice expressed IL-10 mRNA, and not CD4 ϩ T cells from both IL-2Rα KO and IL-2 KO mice.
Discussion
Between 8 and 10% of all peripheral CD4 ϩ T cells express CD25. We have previously shown that the expression of CD25 is constitutive and is not generated by vSAG activation (10) . Indeed, this population is also present in mice free of exogenous and endogenous MMTV (10) , and in vivo activation by MMTV infection does not induce enhanced expression of CD25 (27) . Moreover, when CD4 ϩ CD25 -T cells are injected into nude mice, they do not generate CD25 ϩ T cells upon vSAG activation. Contrary to the CD4 ϩ CD25 -subset which produces IL-2 and not IL-10, the CD4 ϩ CD25 ϩ subset produces IL-10 but not IL-2 and is resistant to clonal deletion induced by vSAG (10). Here we report that CD4 ϩ CD25 ϩ T cells are generated in the thymus, can be maintained in the periphery by expansion, and are fully dependent on IL-2 for 
Sorted CD4 ϩ CD25 -and CD4 ϩ CD25 ϩ lymph node T cells were cultured for 4 days with or without immobilized anti-CD3 and IL-2. Proliferation was assessed after thymidine incorporation. Mean value for three independent experiments performed in triplicate.
Results are expressed as c.p.m.ϫ10 -3 Ϯ SD. growth in vivo and in vitro. CD25 is expressed by thymocyte precursors and by a few CD4 ϩ CD8 ϩ DP cells. We first attempted to determine whether CD4 ϩ CD25 ϩ SP thymocytes were derived directly from CD25 ϩ DP cells. The kinetics of CD25 ϩ thymocyte generation suggested that CD4 ϩ CD25 ϩ SP thymocytes did not derive from the CD25 ϩ DP pool, which yielded no progeny. It thus appears likely that CD4 ϩ CD25 ϩ thymocytes are induced to re-express CD25 at the CD4 ϩ SP mature stage. An alternative explanation is that CD4 ϩ CD25 ϩ T cells in the thymus might be randomly recirculating T cells. This is unlikely, however, as at least half the CD25 ϩ T cells within the thymus were less mature than peripheral T cells. A potential interaction that might lead to re-expression of CD25 on a subpopulation of CD4 ϩ SP T cells remains to be investigated. We know, however, that vSAG encoded by endogenous or exogenous vSAG cannot be involved, as CD4 ϩ CD25 ϩ T cells are also present in MMTV-free mice and are not generated from CD25 -CD4 ϩ T cells by vSAG activation in vivo (10) . In normal mice, CD4 ϩ CD25 ϩ T cells expand gradually from day 10 to a plateau which is reached between 3 and 4 weeks of age in the thymus, and between 4 and 7 weeks in the periphery. Ontogeny of CD4 ϩ CD25 ϩ T cells in the periphery was unmodified by MMTV(SW) infection. In the thymus, vSAGspecific CD4 ϩ CD25 ϩ SP cells were not deleted but were strongly increased, possibly implying that they were activated by vSAG to proliferate. This was not the case, however. Indeed BrdU incorporation and the kinetics of CD25 ϩ thymocyte generation in infected mice do not demonstrate higher proliferation or higher production of CD4 ϩ CD25 ϩ SP thymocytes. CD4 ϩ CD25 ϩ SP T cells could still leave the thymus of infected mice, as shown by analyzing the phenotype of recent thymic migrants. This does not exclude the possibility that some CD25 ϩ cells accumulated in the thymus. Local cytokine production and modification of surface adhesion molecules during infection could be involved in such accumulation.
Additionally (or alternatively) to thymic production, mature T cells can be produced by peripheral expansion (28) . Indeed, CD4 ϩ CD25 ϩ cells have a capacity for peripheral expansion, as shown by transfer of CD4 ϩ T cells into nude mice. Despite the partial specific unresponsiveness induced by MMTV(SW)-vSAG in the CD4 ϩ CD25 ϩ peripheral pool (10), V β 6 ϩ CD25 ϩ T cells from infected mice can still expand as actively in the periphery as cells from normal BALB/c mice. This expansion capacity of CD25 ϩ cells in the periphery may explain why thymectomy performed later than day 3 after birth, when thymus-born CD25 ϩ cells have seeded the periphery, no longer induces autoimmune disease (14) . As after adult thymectomy (as shown here), the level of CD25 ϩ cells can be maintained by peripheral expansion.
One of the main differences between CD4 ϩ CD25 -and CD4 ϩ CD25 ϩ cells is their cytokine profile. CD25 -cells never produce IL-10, even after anti-CD3 stimulation in vitro, which initiates IL-2 production. Conversely, the CD25 ϩ subset does not express IL-2 mRNA, but constitutively expresses IL-10. CD4 ϩ CD25 ϩ T cells are thus the only CD4 subset to produce IL-10 (10). Although an extended cytokine profile has not been analyzed, the CD4 ϩ CD25 ϩ subset can then be classified into the T h 2-type lymphocyte subset. By producing IL-10, CD4 ϩ CD25 ϩ T cells may have a regulatory function on T h 1-type cell function and inflammatory reactions (29) .
Interestingly, mice with a null mutation obtained by homologous recombination in the IL-2Rα (11), IL-2 (15, 30) or IL-10 gene (16) develop the same phenotype of inflammatory bowel disease. In the first case, the absence of CD25-expressing cells seems to be directly responsible (11) . In the second case, we postulated that the absence of IL-2 abrogated CD25 ϩ cell expansion. Indeed, we have shown that CD4 ϩ CD25 ϩ T cells do not express IL-2 mRNA, even after anti-CD3 stimulation (10) . In the present study, we found that CD4 ϩ CD25 ϩ cells were totally dependent on IL-2 for growth: they required exogenous IL-2 to expand in vitro after anti-CD3 cross-linking and, more interestingly, they did not expand in the thymus or periphery of IL-2 KO mice. IL-2 KO mice and IL-2Rα KO mice thus lack the mature CD25 ϩ subpopulation. Interestingly, this is also the case of mice carrying a null mutation for the common cytokine receptor γ chain (J. DiSanto, pers. commun.), which have a reduced thymic cellularity but no block in thymocyte development (31) . The lack of CD25 ϩ cells in IL-2 KO mice, as well as in IL-2Rα KO mice, was associated with the lack of IL-10 mRNA expression, even after anti-CD3 stimulation in vitro. Inflammatory bowel disease in IL-10 KO mice (16) may thus be due to the same mechanism as in IL-2 KO mice and IL-2Rα KO mice. The link between the three types of mice, which develop the same pathologic phenotype, may be the absence of CD4-derived IL-10, either because the CD4 ϩ CD25 ϩ cells producing it are missing or because the IL-10 gene is missing. IL-10 down-regulates the production of inflammatory cytokines (32) and a lack of IL-10 may lead to chronic bowel inflammation through a failure to control the intestinal immune response to common pathogens (16) .
Finally, CD4 ϩ CD25 ϩ T cells may also regulate tolerance induction (33) (34) (35) (36) as well as autoimmune reactions. Indeed, onset of autoimmune diseases in mice thymectomized on day 3 of life corresponds to the absence of the CD25 ϩ subset (12) (13) (14) . A direct role of this lack of CD4 ϩ CD25 ϩ cell-derived IL-10 remains to be demonstrated. However, IL-10 has suppressive effects on antigen presentation via the regulation of MHC class II expression (37) . Enhanced MHC class II antigen expression, together with enhanced inflammatory cytokine production (32) in the absence of IL-10-producing CD4 ϩ T cells, may well be sufficient to initiate autoimmune disease by activating self-reactive T cell clones.
